Poolbeg’s cytokine release syndrome drug shows potential
Data supports Poolbeg’s strategic expansion of POLB 001
Read More
Tag: Poolbeg
Momentum for Poolbeg and CytoReason’s AI collaboration
Partnership establishes several influenza therapy targets using artificial intelligence
Read More
Poolbeg progress oral vaccine programme
Poolbeg’s platform will possess the capability to generate vaccines for a wide range of diseases
Read More
Positive results from Poolbeg Pharma’s human challenge trial
Candidate POLB 001 demonstrates potential in treating multiple influenza conditions
Read More
Poolbeg signs AI deal to advance human challenge data
Collaboration will focus on AI analysis of flu progression, immune responses and the development of new vaccines
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
